Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erbach – page 6

675 clinical trials in Erbach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erbach at a glance
675
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

675 trials in Erbach

Open in trial search

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Crohn's disease

Recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

Phase III Randomized Open‑Label Trial of BNT324 vs Docetaxel Plus Prednisone in Patients with Metastatic Castration‑Resistant Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BNT324
  • Sponsor:BioNTech SE

Study of YMI024 to Reduce Inflammation in Adults with Stable Coronary Artery Disease and Elevated hsCRP

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Obesity

Recruiting

Phase III randomized trial of elecoglipron to assess safety and weight loss in adults with obesity or overweight, with or without type 2 diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Breast neoplasm

Recruiting

Study of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin Acetate
  • Sponsor:Eli Lilly & Co.

Cevostamab plus pomalidomide and dexamethasone in patients with multiple myeloma previously treated with BCMA‑targeted CAR T‑cell therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erbach

What the registry says about research in the country

01 Alzheimer's Disease Research

Groundbreaking clinical trials focusing on early Alzheimer's disease treatments and interventions for associated psychosis. Studies are evaluating novel compounds for managing cognitive decline and neuropsychiatric symptoms.

  • Early-stage disease intervention
  • Psychosis management
  • Cognitive function preservation

Multiple therapeutic approaches targeting both cognitive symptoms and behavioral manifestations of the disease.

02 Migraine Studies

Innovative research examining new treatments for menstrual migraine and chronic migraine conditions. Comparative studies evaluating the effectiveness of different preventive treatments.

  • Preventive treatment protocols
  • Medication comparison studies
  • Gender-specific approaches

Focus on developing targeted therapies for specific types of migraines and their prevention.

03 Multiple Sclerosis Initiatives

Comprehensive research programs investigating treatments for various forms of multiple sclerosis, including progressive and relapsing forms. Studies utilize advanced imaging techniques to track disease progression.

  • Progressive MS treatments
  • Brain atrophy assessment
  • Disability progression prevention

Advanced therapeutic approaches targeting different disease manifestations and progression patterns.

04 Parkinson's Disease Studies

Innovative research focusing on early-onset Parkinson's disease, examining long-term treatment efficacy and brain pathophysiology changes. Studies aim to understand disease progression and therapeutic interventions.

  • Early intervention strategies
  • Long-term treatment effects
  • Disease modification approaches

Emphasis on understanding disease mechanisms and developing targeted therapeutic solutions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.